Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update.


Journal

Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487

Informations de publication

Date de publication:
Historique:
received: 06 05 2020
accepted: 15 09 2020
pubmed: 27 10 2020
medline: 25 2 2023
entrez: 26 10 2020
Statut: ppublish

Résumé

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targets genes by binding to the 3'-untranslated regions. They play vital roles in diverse biological processes, including the development of hepatic fibrosis (HF). HF is characterized by the accumulation of extracellular matrix (ECM) and hepatic stellate cells (HSCs) are considered a major cell type for producing ECM. Alteration of the HSC phenotype plays a crucial role in the HF pathological process. MiRNAs involved in various biological process, such as differentiation, apoptosis, migration, and their relevant signaling pathways, are expressed in HSCs; however, emerging evidence indicates that numerous miRNAs are abnormally expressed in activated HSCs. In this review, we summarize the categorization of miRNAs in HF and describe the relationships among them. We also discuss miRNAs recently discovered to be related to HF, and attempt to find potential miRNAs that may serve as novel biomarkers for use in HF treatment.

Identifiants

pubmed: 33100194
pii: CPD-EPUB-110878
doi: 10.2174/1381612826666201023143542
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3000-3011

Subventions

Organisme : National Science Foundation of China
ID : 81970534

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Sai Zhu (S)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Xin Chen (X)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Yu Chen (Y)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Xiao-Feng Li (XF)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Si-Yu Chen (SY)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Juan-Juan Li (JJ)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Ao Wang (A)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Cheng Huang (C)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Jun Li (J)

Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Anhui, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH